Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4).

被引：0
|
作者：
Li, Jianyong
Tao, Rong
Fan, Lei
Song, Yongping
Hu, Yu
Zhang, Wei
Wang, Yafei
Xu, Linxinyu
Sun, Xing
Zhou, Hui
机构：
[1] Jiangsu Prov Hosp, Nanjing, Peoples R China
[2] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Henan Canc Hosp, Zhengzhou, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[6] Peking Union Med Coll Hosp, Beijing, Peoples R China
[7] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[8] Innovent Biol Inc, Suzhou, Peoples R China
[9] Innovent Biol Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8050
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4).
    Tao, Rong
    Fan, Lei
    Song, Yongping
    Hu, Yu
    Zhang, Wei
    Wang, Yafei
    Xu, Linxinyu
    Zhou, Hui
    Li, Jianyong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
    Tao, Rong
    Fan, Lei
    Song, Yongping
    Hu, Yu
    Zhang, Wei
    Wang, Yafei
    Xu, Wei
    Li, Jianyong
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [3] Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
    Rong Tao
    Lei Fan
    Yongping Song
    Yu Hu
    Wei Zhang
    Yafei Wang
    Wei Xu
    Jianyong Li
    Signal Transduction and Targeted Therapy, 6
  • [4] Sintilimab for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 13 - 14
  • [5] Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.
    Su, Hang
    Song, Yongping
    Jiang, Wenqi
    Sun, Xiuhua
    Qian, Wenbin
    Zhang, Wei
    Gao, Yuhuan
    Jin, Zhengming
    Zhou, Jianfeng
    Jin, Chuan
    Zou, Liqun
    Qiu, Lugui
    Li, Wei
    Yang, Jianmin
    Hou, Ming
    Zeng, Shan
    Liu, Peng
    Shi, Yuankai
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] PENPULIMAB FOR RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN'S LYMPHOMA (CHL): EXTENDED FOLLOW-UP OF THE MULTICENTER, SINGLE-ARM, PHASE 2 STUDY
    Song, Yuqin
    Zhou, Keshu
    Jin, Chuan
    Qian, Zhengzi
    Hou, Ming
    Fan, Lei
    Li, Fei
    Ding, Kaiyang
    Zhou, Hui
    Li, Xiaoling
    Chen, Bing
    Sun, Xiuhua
    Song, Xianmin
    Jiang, Ming
    Zhang, Qingyuan
    Liu, Lihong
    Yu, Guohua
    Hu, Yu
    Zhao, Zheng
    Liu, Ligen
    Xue, Hongwei
    Luo, Jun
    He, Bai
    Yao, Zhifang
    Xu, Fenghua
    Zhao, Min
    Li, Baiyong
    Xia, Yu
    Zhu, Jun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A598 - A598
  • [7] Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH)
    Liu, Chuanxu
    Gao, Yan
    Yu, Yang
    Guo, Zhi
    Zhao, Jun
    Tao, Rong
    Huang, Huiqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.
    Su, Hang
    Song, Yongping
    Jiang, Wenqi
    Sun, Xiuhua
    Qian, Wenbin
    Zhang, Wei
    Gao, Yuhuan
    Jin, Zhengming
    Zhou, Jianfeng
    Jin, Chuan
    Zou, Liqun
    Qiu, Lugui
    Li, Wei
    Yang, Jianmin
    Hou, Ming
    Zeng, Shan
    Liu, Peng
    Shi, Yuankai
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study
    Wu, Jianqiu
    Song, Yuqin
    Chen, Xinchuan
    Lin, Tongyu
    Cao, Junning
    Liu, Yanyan
    Zhao, Yaozhong
    Jin, Jie
    Huang, Haiwen
    Hu, Jianda
    Luo, Jun
    Zhang, Liling
    Xue, Hongwei
    Zhang, Qingyuan
    Wang, Weiwei
    Chen, Chunxia
    Feng, Jifeng
    Zhu, Jun
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (06) : 984 - 992
  • [10] GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL).
    Huang, Huiqiang
    Tao, Rong
    Yang, Yu
    Cen, Hong
    Zhou, Hui
    Guo, Ye
    Zou, Liqun
    Cao, Junning
    Huang, Yunhong
    Jin, Jie
    Zhang, Liling
    Yang, Haiyan
    Xing, Xiaojing
    Zhang, Huilai
    Liu, Yanyan
    Zhu, Xiaoli
    Fang, Teng
    Dai, Hangjun
    Qi, Qinzhou
    Yang, Jason
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345